Current Edition

Upcoming Events



The Benefits of Outsourcing for Early-stage Drug Development

The investment drug companies are making into producing biosimilars has never been greater. This major push is driven by the faster time to market of a biosimilar product compared to a novel drug, achieved through the greater emphasis on analytical investigations into the product and a decreased clinical trial requirement. Richard L. Easton and Andrew J. Reason at BioPharmaSpec Ltd evaluate the benefits of outsourcing for early-stage drug development.